Scientific Program - Retina

Print
Please see below the COPHy AA ScientificProgram. Please click on the appropriate section to view the relevant program. Please note that the program is subject to change. To view the program timetable / overview, please click here

Retina
Glaucoma Anterior Segment Neuro-ophthalmology
FRIDAY, FEBRUARY 22, 2019
HALL A
08:00-08:30
OPENING REMARKS| Controversies in Ophthalmolgy - Asia/Australia 2019
Chairs:
Neil Bressler, USA, Yizhi Liu, China and Ningli Wang, China
08:00-08:10
Welcome to COPHy AA 2019: Neil Bressler, USA
08:10-08:20
The Importance of Vision in China, throughout Asia/Australia, and the World
08:20-08:30 Asian/Australian 2019 Recipients of Global Ophthalmology Awards Program (GOAP)
08:30-10:00
OPENING SESSION | Big Controversies in Ophthalmology in 2019
Chairs:
Neil Bressler, USA
08:30-09:00
Debate I: Proliferative diabetic retinopathy: Five-year outcomes confirm anti-VEGF without PRP is an acceptable initial treatment
08:30-08:40
08:40-08:50
08:50-09:00
Yes: Susan Bressler, USA
No: Tien Yin Wong, Singapore
Discussion
09:00-09:30
Debate II: Neuro-protection in glaucoma: A viable pursuit
09:00-09:10
09:10-09:20
09:20-09:30
Yes: Christopher Leung, Hong Kong
No: Ningli Wang, China
Discussion
09:30-10:00
Debate III: Removal cataract worsens macular degeneration
09:30-09:40
09:40-09:50
09:50-10:00
Yes:
No: 
Discussion
10:00-10:30 Visit to Exhibits - Coffee and Refreshment Break
10:30-12:00
RETINA I | Choroidal Neovascular Age-related Macular Degeneration
Chairs:
Adrian Koh, Singapore, Xiaoxin Li, China and Xiaoling Liang, China
10:30-11:00
Debate I: Treat and extend regimens are superior to PRN regimens
10:30-10:40
10:40-10:50
10:50-11:00
Yes: Gemmy Cheung, Singapore
No: Susan Bressler, USA
Discussion
11:00-11:30
Debate II: Large submacular hemorrhages typically should be managed initially with surgery, not anti-VEGF injections
11:00-11:10
11:10-11:20
11:20-11:30
Yes: Yaiji Sakamoto, Japan
No: Paisan Ruamviboonsuk, Thailand
Discussion
11:30-12:00
 
Debate III: New agents or delivery devices represents a clinically relevant advance in managing neovascular AMD
11:30-11:40
11:40-11:50
11:50-12:00
Yes: Jun Kong, China
No: Sherman Valero, Philippines
Discussion
12:00-12:15 Visit to Exhibits & Technical Break
12:15-13:15 INDUSTRY-SPONSORED LUNCHEON SYMPOSIUM (NOT FOR CME)
13:15-13:45 Visit to Exhibits - Dessert Break
13:45-15:15
RETINA II | Diabetic Macular Edema
Chairs: Susan Bressler, USA , Xiaofeng Lin, China and Wenbin Wei, China
13:45:14:15 Debate I: Consider alternative treatment regimens for patients with suboptimal vision responses after first 3 intravitreal anti-VEGF injections
13:45-13:55
13:55-14:05
14:05-14:15
Yes: Michaella Goldstein, Israel
No: Voraporn Chikitmongkol, Thailand
Discussion
14:15-14:45 Debate II: For persistent DME after 6 injections, add focal/grid laser
14:15-14:25
14:25-14:35
14:35-14:45
Yes: Jun Kong, China
No: Timothy Lai, Hong Kong
Discussion
14:45-15:15 Debate III: Artificial intelligence is ready to be used widely for DR Screening
14:45-14:55
14:55-15:05
15:05-15:15
Yes
No: Daniel Ting, Singapore
Discussion
15:15-16:45 RETINA III| Retinal Detachment and Vitrectomy
Chairs: Joseph Moisseiev, Israel and Taiji Sakamoto, Japan
15:15-15:45 Debate I: Non-clearing vitreous hemorrhage in PDR: Try a series of anti-VEGF injections before going to vitrectomy
15:15-15:25
15:25-15:35
15:35-15:45
Yes: Adrian Koh, Singapore
No: Taiji Sakamoto, Japan
Discussion
15:45-16:15 Debate II: Vitrectomy alone is superior to a scleral buckle for a total RD with small tear at 1 o'clock in a phakic 40-year old eye
15:45-15:55
15:55-16:05
16:05-16:15
Yes: Adiel Barak, Israel
No: Joseph Moisseiev, Israel
Discussion
16:15-16:45 Debate III: Attempt to treat focal vitreomacular traction with gas injection should be tried before considering vitrectomy
16:15-16:25
16:25-16:35
16:35-16:45
Yes: Shibo Tang, China
No: Adiel Barak, Israel
Discussion
END OF DAY FRIDAY HALL A

SATURDAY, FEBRUARY 23, 2019
HALL A
09:00-10:00
Vision Academy in Retina 2019
Chairs:
Neil Bressler, USA and Taiji Sakamoto, Japan
09:00-09:10 An introduction to Vision Academy: Neil Bressler, USA
09:10-09:30
Debate I: The fellow eye of a patient who has CNV being treated in the first eye should be monitered using sophisticated home monitoring technology
09:10-09:15
09:15-09:20
09:20-09:25
09:25-09:30
Yes: Anat Loewenstein, Israel
No
Presentation of viewpoint: Neil Bressler, USA
Questions
09:30-09:50
Debate II: Futility of treatment: In some cases in which no improvement is anticipated treatment should be stopped
09:30-09:35
09:35-09:40
09:40-09:45
09:45-09:50
Yes
No: Taiji Sakamoto, Japan
Presentation of viewpoint: Anat Loewenstein, Israel
Questions
09:50-10:00 Looking forward with the Vision Academy: Anat Loewenstein, Israel
10:00-10:30 Visit to Exhibits - Coffee and Refreshment Break
10:30-12:00
RETINA IV | Polypoidal Choroidal Vasculopathy
Chairs: Adrian Koh, Singapore and Won Ki Lee, Republic of Korea
10:30-11:00 Debate I: EVEREST 2 and PLANET results should be compared
10:30-10:40
10:40-10:50
10:50-11:00
Yes: Won Ki Lee, Republic of Korea
No: Adrian Koh, Singapore
Discussion
11:00-11:30 Debate II: ICG Angiography is needed to manage most cases of PCV
11:00-11:10
11:10-11:20
11:20-11:30
Yes: Fenghua Wang, China
No: Voroporn Chaikitmongkol, Thailand
Discussion
11:30-12:00 Debate III: OCT-Angiography is useful in management of PCV
11:30-11:40
11:40-11:50
11:50-12:00
Yes: Gemmy Cheung, Singapore
No: Timothy Lai, Hong Kong
Discussion
12:00-12:15 Visit to Exhibition & Lunch Box Pick Up
12:15-13:15 INDUSTRY-SPONSORED LUNCHEON SYMPOSIUM (NOT FOR CME)
13:15-13:45 Visit to Exhibits - Dessert Break
13:45-15:15
RETINA V | Pathologic Myopia
Chairs: Joseph Moisseiev, Israel and Hua Yan, China
13:45:14:15 Debate I: PDT rather than thermal laser should be used for discrete non-foveal leaks in central serous retinopathy
13:45-13:55
13:55-14:05
14:05-14:15
Yes
No
Discussion
14:15-14:45 Debate II: Macular hemorrhage without leakage on fluorescein or ICG angiography should be treated empirically with anti-VEGF therapy or PDT with verteporfin for possible choroidal neovascularization obscured by hemorrhage
14:15-14:25
14:25-14:35
14:35-14:45
Yes: Young Hee Yoon, Republic of Korea
No: Shibo Tang, China
Discussion
14:45-15:15 Debate III: Myopic foveoschisis should be treated by vitrectomy
14:45-14:55
14:55-15:05
15:05-15:15
Yes: Joseph Moissieiv, Israel
No: Adiel Barak, Israel
Discussion
15:15-16:45
RETINA VI | Retinal Vein Occlusions
Chairs: Timothy Lai, Hong Kong, Xiaoling Liang, China and Young Hee Yoon, Republic of Korea
15:15-15:45 Debate I: Intravitreal steroids are a viable choice as first line therapy
15:15-15:25
15:25-15:35
15:35-15:45
Yes: Barry Kuppermann, USA
No: Gemmy Cheung, Singapore
Discussion
15:45-16:15 Debate II: SCORE 2 results: Choose aflibercept over bevacizumab for macular edema secondary to central retinal vein occlusion
15:45-15:55
15:55-16:05
16:05-16:15
Yes: Susan Bressler, USA
No: Young Hee Yoon, Republic of Korea
Discussion
16:15-16:45 Debate III: Unilateral retinal vein occlusions in older individuals typically warrant work-up for systemic disease
16:15-16:25
16:25-16:35
16:35-16:45
Yes: Paisan Ruamviboonsuk, Thailand
No
Discussion
17:00-18:30
Think Tank: Controversies Across Ophthalmology
Chairs: Tin Aung, Singapore, Xiaxin Li, China and Paisan Ruamviboonsuk, Thailand
17:00-17:30 Debate I: Creation of a cataract in the presence of diabetic macular edema is a concern
17:00-17:10
17:10-17:20
17:20-17:30
Yes
No: Barry Kuppermann, USA
Discussion
17:30-18:00 Debate II: Big data are the next big thing in ophthalmology
17:30-17:40
17:40-17:50
17:50-18:00
Yes: Daniel Ting, Singapore
No: Sherman Valero, Philippines
Discussion
18:00-18:30 Spirinolactone is effective as a treatment for CSR
18:00-18:10
18:10-18:20
18:20-18:30
Yes
No: Michaella Goldstein, Israel
Discussion
END OF DAY SATURDAY HALL A